Thank you for your interest in our study titled:

"Alcohol Use Disorder and Cannabis: Testing Novel Harm Reduction Strategies" 

(SONAR)


If you join the study, you will be randomized to receive one of three study medications that you will take for 12 weeks: (1) 210 mg/day of CBD that includes trace amounts of THC (< 0.3%), or (2) 210 mg/day of CBD that consists of no THC, or (3) 210 mg/day of Hemp Seed Oil, which does not contain any CBD or THC. You will not know which medication group you are in until the completion of the study, and we ask that you not use any other form of cannabis during those 12 weeks.

There will be a study visit approximately every week during the 12 weeks you are taking the study medication, with another online follow-up four weeks later. The first study visit will take place at the University of Colorado Anschutz Medical Campus. After that, there will be an additional three visits that will also take place at the University of Colorado Anschutz Medical Campus. The other eleven visits will be remote via Zoom. Visits may include a breathalyzer test, a blood draw, a drug and pregnancy screen, an alcohol exposure task, and surveys and questionnaires, depending on the week. Total study participation will last 16 weeks.

Before we schedule your first appointment, it would be helpful to see if you will likely qualify for the study. To do this, I would like to ask you some eligibility questions about your health, including prior and current alcohol and drug use. It should take about 10 minutes to go through these questions. Some of the questions may make you uncomfortable; you do not have to answer any question you would not like to answer, but without answers to these questions, you will not be eligible to participate in the study. We will only save your name or any other information that would identify you once we know you have qualified for the study; at that time, we will keep this information secure. If you do not qualify for this study, we will immediately destroy any information we have collected. We are also required to give you the number of COMIRB, the Ethics Board that oversees our research: it is 303.724.1055, in case you have any questions or concerns for them.

Loading... Loading...
You have selected an option that triggers this survey to end right now.
To save your responses and end the survey, click the 'End Survey' button below. If you have selected the wrong option by accident and/or wish to return to the survey, click the 'Return and Edit Response' button.